Drugs / CYT003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02087644 | May 2014 | asthma | Cytos Biotechnology AG | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT01673672 | Nov 2012 → May 2014 | chronic asthma | Cytos Biotechnology AG | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYT003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01673672 ↗ |
| Known as | CYT003-QbG10 | “A Randomized, Placebo-Controlled, Phase IIb Study of CYT003-QbG10 (CYT003), a TLR9 Agonist, in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on...” NCT02087644 ↗ |
| Action | Activate | “a TLR9-agonist” NCT01673672 ↗ |
| Route | Subcutaneous | “7 subcutaneous injections, weekly/biweekly within 10 weeks” NCT01673672 ↗ |
| Target | TLR9 | “a TLR9-agonist” NCT01673672 ↗ |